Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice
Abstract Background Atherosclerosis (AS) is a major contributor to vascular disorders and represents a significant risk to human health. Currently, first-line pharmacotherapies are associated with substantial side effects, and the development of atherosclerosis is closely linked to dietary factors....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | BMC Cardiovascular Disorders |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12872-025-04497-y |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572019300892672 |
|---|---|
| author | Yaze Wang Hifumi Ohishi Rongji Wu Hui Liu Rong Xu |
| author_facet | Yaze Wang Hifumi Ohishi Rongji Wu Hui Liu Rong Xu |
| author_sort | Yaze Wang |
| collection | DOAJ |
| description | Abstract Background Atherosclerosis (AS) is a major contributor to vascular disorders and represents a significant risk to human health. Currently, first-line pharmacotherapies are associated with substantial side effects, and the development of atherosclerosis is closely linked to dietary factors. This study evaluated the effects of a dietary supplement, EsV3, on AS in apolipoprotein E (ApoE) −/− model mice. Methods The study utilized a high-fat diet-induced ApoE−/− hyperlipidemic mouse model. EsV3 was administered in prophylactic (P-EsV3) and therapeutic regimens for 16 and 12 weeks, respectively, with distinct high- and low-dose groups (0.36 and 1.8 g/kg/day). Serum lipid levels were measured and monitored for body weight and food consumption alterations in murine models. Aortic oil red O staining was conducted to assess plaque formation and calculate the plaque-to-vessel area ratio. Liver tissue changes were examined via HE staining. Moreover, serum oxidative stress markers (MDA, GSH, SOD) were measured to evaluate oxidative damage and lipid metabolism. Results Both atorvastatin and P-EsV3 treatments significantly lowered TC, TG, and LDL-C levels, with P-EsV3-H enhancing HDL-C levels (P < 0.05). Prophylactic EsV3 administration was more effective than therapeutic administration in regulating TG and LDL-C levels and had comparable effects to atorvastatin on TC and HDL-C. All treatment groups exhibited reduced body weight compared to the model group, with no significant differences in food intake. Additionally, EsV3 administration significantly reduced the aortic plaque area and liver lipid droplets compared to the model group, while mitigating oxidative stress, as evidenced by decreased MDA levels and increased SOD and GSH levels, with outcomes comparable to those observed with atorvastatin. Conclusions In ApoE−/− hyperlipidemic mice, EsV3 improved lipid profiles and reduced aortic plaque formation. EsV3's effects, attributed partly to its antioxidant properties, were comparable to atorvastatin, suggesting its potential as a preventive and therapeutic agent for hyperlipidemia and atherosclerosis. |
| format | Article |
| id | doaj-art-9ae42bb221b14ad1a8a59894e903c2f3 |
| institution | Kabale University |
| issn | 1471-2261 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cardiovascular Disorders |
| spelling | doaj-art-9ae42bb221b14ad1a8a59894e903c2f32025-02-02T12:07:48ZengBMCBMC Cardiovascular Disorders1471-22612025-01-0125111110.1186/s12872-025-04497-yProphylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− miceYaze Wang0Hifumi Ohishi1Rongji Wu2Hui Liu3Rong Xu4Department of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and TechnologyInstitute of Hydrox IncEiho Technology (WUHAN) Co., LtdDepartment of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and TechnologyDepartment of Pharmacology, School of Basic Medicine, Tongji Medical College, Huazhong University of Science and TechnologyAbstract Background Atherosclerosis (AS) is a major contributor to vascular disorders and represents a significant risk to human health. Currently, first-line pharmacotherapies are associated with substantial side effects, and the development of atherosclerosis is closely linked to dietary factors. This study evaluated the effects of a dietary supplement, EsV3, on AS in apolipoprotein E (ApoE) −/− model mice. Methods The study utilized a high-fat diet-induced ApoE−/− hyperlipidemic mouse model. EsV3 was administered in prophylactic (P-EsV3) and therapeutic regimens for 16 and 12 weeks, respectively, with distinct high- and low-dose groups (0.36 and 1.8 g/kg/day). Serum lipid levels were measured and monitored for body weight and food consumption alterations in murine models. Aortic oil red O staining was conducted to assess plaque formation and calculate the plaque-to-vessel area ratio. Liver tissue changes were examined via HE staining. Moreover, serum oxidative stress markers (MDA, GSH, SOD) were measured to evaluate oxidative damage and lipid metabolism. Results Both atorvastatin and P-EsV3 treatments significantly lowered TC, TG, and LDL-C levels, with P-EsV3-H enhancing HDL-C levels (P < 0.05). Prophylactic EsV3 administration was more effective than therapeutic administration in regulating TG and LDL-C levels and had comparable effects to atorvastatin on TC and HDL-C. All treatment groups exhibited reduced body weight compared to the model group, with no significant differences in food intake. Additionally, EsV3 administration significantly reduced the aortic plaque area and liver lipid droplets compared to the model group, while mitigating oxidative stress, as evidenced by decreased MDA levels and increased SOD and GSH levels, with outcomes comparable to those observed with atorvastatin. Conclusions In ApoE−/− hyperlipidemic mice, EsV3 improved lipid profiles and reduced aortic plaque formation. EsV3's effects, attributed partly to its antioxidant properties, were comparable to atorvastatin, suggesting its potential as a preventive and therapeutic agent for hyperlipidemia and atherosclerosis.https://doi.org/10.1186/s12872-025-04497-yAtherosclerosisHyperlipidemiaEsV3Dietary supplementOxidative damage |
| spellingShingle | Yaze Wang Hifumi Ohishi Rongji Wu Hui Liu Rong Xu Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice BMC Cardiovascular Disorders Atherosclerosis Hyperlipidemia EsV3 Dietary supplement Oxidative damage |
| title | Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice |
| title_full | Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice |
| title_fullStr | Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice |
| title_full_unstemmed | Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice |
| title_short | Prophylactic and therapeutic effects of EsV3 on atherosclerotic lesions in ApoE−/− mice |
| title_sort | prophylactic and therapeutic effects of esv3 on atherosclerotic lesions in apoe mice |
| topic | Atherosclerosis Hyperlipidemia EsV3 Dietary supplement Oxidative damage |
| url | https://doi.org/10.1186/s12872-025-04497-y |
| work_keys_str_mv | AT yazewang prophylacticandtherapeuticeffectsofesv3onatheroscleroticlesionsinapoemice AT hifumiohishi prophylacticandtherapeuticeffectsofesv3onatheroscleroticlesionsinapoemice AT rongjiwu prophylacticandtherapeuticeffectsofesv3onatheroscleroticlesionsinapoemice AT huiliu prophylacticandtherapeuticeffectsofesv3onatheroscleroticlesionsinapoemice AT rongxu prophylacticandtherapeuticeffectsofesv3onatheroscleroticlesionsinapoemice |